Table 2.
Association of Pi10 with respiratory COPD medication.
| Predictor | Regression coefficient B | Standard error of B |
p value (compared with ref.) |
95% CI lower | 95% CI upper |
|---|---|---|---|---|---|
| GOLD 1 | ref | ||||
| GOLD 2 | 0.023 | 0.011 | 0.043 | 0.001 | 0.045 |
| GOLD 3 | 0.038 | 0.012 | 0.002 | 0.014 | 0.062 |
| GOLD 4 | 0.043 | 0.016 | 0.009 | 0.011 | 0.076 |
| GOLD A | ref | ||||
| GOLD B | 0.004 | 0.009 | 0.664 | −0.013 | 0.021 |
| GOLD C | 0.002 | 0.011 | 0.847 | −0.020 | 0.024 |
| GOLD D | 0.028 | 0.010 | 0.008 | 0.007 | 0.048 |
| Triple | −0.022 | 0.007 | 0.003 | −0.036 | −0.007 |
| Annual delta FVC % predicted | 0.002 | 0.001 | 0.009 | 0.001 | 0.004 |
COPD, chronic obstructive pulmonary disease; FVC, forced vital capacity.
The table shows the results of multivariate linear regression analysis in terms of non-standardized regression coefficients (B), their standard errors, p values and 95% confidence intervals. All GOLD grades and groups refer to visit 4, the change of FVC % predicted to that between baseline and each patient’s last visit, expressed as % predicted at baseline. Significant differences (p < 0.05) are marked in bold.